The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
ENZA-p: A randomized phase II trial using PSMA as a therapeutic agent and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901).
 
Louise Emmett
Honoraria - Astellas Pharma; AstraZeneca; Janssen Oncology; Mundipharma; Telix Pharmaceuticals
Consulting or Advisory Role - Noxopharm
Speakers' Bureau - Janssen Oncology; Janssen Oncology; mundipharma
Research Funding - Novartis (Inst); Novartis (Inst); Noxopharm (Inst); Noxopharm (Inst)
 
Shalini Subramaniam
No Relationships to Disclose
 
Andrew James Martin
No Relationships to Disclose
 
Alison Yan Zhang
Honoraria - Astellas Pharma; AstraZeneca; Bayer; MSD Oncology; Mundipharma; Pfizer (Inst)
Consulting or Advisory Role - Janssen Oncology; Merck; Merck Sharp & Dohme; Pfizer
Travel, Accommodations, Expenses - Astellas Pharma; Ipsen
 
Sonia Yip
No Relationships to Disclose
 
Megan Crumbaker
Honoraria - Bayer; Merck
Consulting or Advisory Role - Pfizer
Travel, Accommodations, Expenses - MSD Oncology
 
Nisha Rana
No Relationships to Disclose
 
Roslyn J. Francis
No Relationships to Disclose
 
Michael S Hofman
Consulting or Advisory Role - Endocyte; Janssen; POINT Biopharma
Speakers' Bureau - Astellas Pharma; AstraZeneca; Janssen; Mundipharma
Research Funding - Advanced Accelerator Applications/Novartis (Inst); Endocyte (Inst)
Travel, Accommodations, Expenses - Genzyme; Ipsen; Janssen
 
Anthony M. Joshua
Stock and Other Ownership Interests - Pricilium Therapeutics
Consulting or Advisory Role - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Ipsen (Inst); IQvia (Inst); Janssen Oncology (Inst); Merck Serono (Inst); Neoleukin Therapeutics (Inst); Novartis (Inst); Noxopharm (Inst); Pfizer (Inst); Sanofi (Inst)
Research Funding - AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); Janssen Oncology (Inst); Lilly (Inst); Lilly (Inst); Macrogenics (Inst); Mayne Pharma (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Roche/Genentech (Inst)
 
Shahneen Kaur Sandhu
Honoraria - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); Merck Serono (Inst)
Consulting or Advisory Role - AstraZeneca (Inst); Bristol-Myers Squibb/Roche (Inst); Merck Sharpe & Dohme (Inst)
Speakers' Bureau - Bristol-Myers Squibb; Merck; Roche/Genentech
Research Funding - Amgen (Inst); AstraZeneca (Inst); Endocyte/Advanced Accelerator Applications (Inst); Genentech/Roche (Inst); Merck (Inst); Novartis (Inst)
 
Arun Azad
Honoraria - Aculeus Therapeutics; Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Ipsen; Janssen; Merck Serono; Merck Sharp & Dohme; Novartis; Noxopharm; Pfizer; Sanofi; Telix Pharmaceuticals; Tolmar
Consulting or Advisory Role - Aculeus Therapeutics; Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Ipsen; Janssen; Merck Serono; Merck Sharp & Dohme; Novartis; Noxopharm; Pfizer; Sanofi; Telix Pharmaceuticals; Tolmar
Speakers' Bureau - Amgen; Astellas Pharma; Bayer; Bristol-Myers Squibb; Ipsen; Janssen; Merck Serono; Novartis
Research Funding - Aptevo Therapeutics (Inst); Astellas Pharma; Astellas Pharma (Inst); AstraZeneca; AstraZeneca (Inst); Bionomics (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Ipsen (Inst); MedImmune (Inst); Merck Serono; Merck Serono (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst); Synthorx (Inst)
Travel, Accommodations, Expenses - Amgen; Astellas Pharma; Janssen; Merck Serono; Pfizer; Sanofi; Tolmar
 
Craig Gedye
Consulting or Advisory Role - Abbvie (Inst); Bristol-Myers Squibb (Inst); Ipsen (Inst); Merck Sharp & Dohme (Inst); Novotech; Pfizer (Inst)
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Merck Sharp & Dohme (Inst)
 
Andrew James Weickhardt
Honoraria - Eisai; Merck Sharp & Dohme
Consulting or Advisory Role - Bristol-Myers Squibb; Merck Sharp & Dohme; Pfizer
Speakers' Bureau - Astellas Pharma
Research Funding - Merck
Travel, Accommodations, Expenses - Astellas Pharma; Ipsen; Merck Sharp & Dohme
 
Jeffrey C. Goh
Stock and Other Ownership Interests - Icon Cancer Care
Honoraria - Eisai
Consulting or Advisory Role - Bristol-Myers Squibb; Janssen; Merck Sharp & Dohme Oncology
Speakers' Bureau - AstraZeneca; MSD
Research Funding - BeiGene
 
Siobhan Ng
No Relationships to Disclose
 
Mark Voskoboynik
Consulting or Advisory Role - AstraZeneca
 
Margaret Mary McJannett
Employment - Anzup
 
Martin R. Stockler
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Bionomics (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Medivation (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst); Tilray (Inst)
Travel, Accommodations, Expenses - Medivation/Pfizer
 
Ian D. Davis
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Exelixis (Inst); Ipsen (Inst); Janssen Oncology (Inst); Medivation (Inst); Movember Foundation (Inst); MSD Oncology (Inst); Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst)
Patents, Royalties, Other Intellectual Property - International Patent Application No: PCT /US2004/032147 (NY-ESO-1) through Ludwig Institute for Cancer Research.